Xilio Therapeutics (NASDAQ:XLO – Get Free Report) and Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Institutional and Insider Ownership
54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Xilio Therapeutics and Phathom Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xilio Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Phathom Pharmaceuticals | 0 | 1 | 3 | 0 | 2.75 |
Volatility & Risk
Xilio Therapeutics has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Valuation and Earnings
This table compares Xilio Therapeutics and Phathom Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xilio Therapeutics | N/A | N/A | -$76.40 million | ($2.57) | -0.40 |
| Phathom Pharmaceuticals | $680,000.00 | 976.93 | -$201.59 million | ($4.41) | -2.57 |
Xilio Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Xilio Therapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xilio Therapeutics | N/A | -153.48% | -89.26% |
| Phathom Pharmaceuticals | N/A | N/A | -66.97% |
Summary
Phathom Pharmaceuticals beats Xilio Therapeutics on 8 of the 12 factors compared between the two stocks.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
